In recent years, a growing number of researchers have sounded alarms about disruptions to health solutions science, a field focused on improving how healthcare is delivered, rather than discovering new treatments. The field, which includes health services research, addresses critical questions such as how to ensure patients receive existing effective interventions and how to optimize healthcare systems to prevent disease and improve outcomes. However, funding and support for this type of research have been limited—and recent budget and staffing cuts have further imperiled ongoing projects.
One example involves a trial led by Dr. Suchitra Rao, a pediatrician in Colorado, studying whether hospitals can better identify and vaccinate high-risk children against influenza before discharge. The study came in response to a tragic case of a teenager with a congenital heart defect and a weakened immune system who missed an annual flu vaccine, subsequently contracting influenza and dying from complications. Dr. Rao’s multi-site randomized controlled trial, funded by the Agency for Healthcare Research and Quality (AHRQ), was designed to see if flu vaccination in the hospital could prevent such outcomes. The trial was nearing its third year of a planned five-year study when the federal government abruptly cut funding in July 2025.
This funding lapse occurred alongside a broader dismantling of AHRQ’s research capacity. Although the agency retained a budget close to prior years for fiscal 2026, ongoing mass layoffs have reduced its staff by approximately 75 percent, and it has not issued new research grants since April 2025. These developments have forced the early termination of a number of studies across the United States focused on hospital care delivery improvements.
Other studies affected include one led by Dr. Michelle Kelly in Wisconsin, which tested real-time electronic health record note access for parents of hospitalized children. Initial findings showed note access dramatically increased family engagement and identified potential safety concerns, but full trial enrollment was halted after 150 families. Similarly, Dr. Valerie Vaughn’s study in Utah aiming to reduce inappropriate antibiotic prescriptions at hospital discharge was cut short, despite the public health importance of combating antibiotic resistance.
When investigators received notifications of cancellations, AHRQ cited a strategic focus on priorities such as patient safety, antibiotic stewardship, telehealth, artificial intelligence, nutrition, and autism research. However, earlier funded projects addressing these same themes were among those discontinued. For example, trials exploring telehealth for pediatric asthma and digital tools to aid autism diagnosis were also canceled midstream.
Experts warn that ending studies prematurely not only wastes significant taxpayer resources but also leaves pressing healthcare delivery questions unanswered. The absence of rigorous evidence may hinder efforts to translate proven medical advances into practical, life-saving interventions for vulnerable populations.
As the United States continues to invest heavily in biomedical research—spending more than $5 trillion annually on healthcare—the debate around the balance between discovering new treatments and ensuring their effective delivery is intensifying. Observers note that while biomedical invention is critical, ensuring patients actually receive timely and appropriate care remains a major challenge that requires sustained scientific attention and funding. Without that, breakthroughs risk going unused, and preventable tragedies may continue.